Are Metaneb (intermittent positive‑pressure aerosol delivery) and Volara (high‑flow nasal cannula) effective therapies?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Metaneb and Volara Therapy Effectiveness

Based on current evidence, Metaneb (high-frequency assisted airway clearance with integrated nebulizer) demonstrates superior aerosol delivery efficiency compared to Volara, while high-flow nasal cannula (HFNC) systems like Volara show effectiveness for post-extubation respiratory support but are inferior to CPAP for acute hypoxemic respiratory failure.

Metaneb vs Volara for Aerosol Delivery

The most recent head-to-head comparison reveals significant performance differences 1:

For aerosol delivery during airway clearance therapy, Metaneb (BiWaze Clear system) substantially outperforms Volara:

  • Lung deposition during PEP therapy (10 cm H2O): 28% vs 6.2% (p<0.001)
  • Lung deposition during oscillatory therapy (20 cm H2O): 16.3% vs 7.3% (p=0.005)

The Volara's poor performance stems from:

  • Excessive nebulizer residual losses (55-59% vs 3-7% with Metaneb)
  • High fugitive aerosol losses through handset leak valves (22-23% vs 3-4%)
  • Inefficient circuit design that wastes medication

Clinical implication: If your goal is effective medication delivery to the lungs during airway clearance, Metaneb is the clear choice. Volara wastes the majority of nebulized medication.

Volara/HFNC for Respiratory Support

British Thoracic Society guidelines recognize HFNC as a legitimate oxygen delivery option 2:

  • HFNC is well-tolerated for hypoxic patients requiring medium-to-high concentration oxygen who are NOT at risk of hypercapnia
  • Should NOT be used as first-line in patients at risk of CO2 retention

Post-Extubation Context

For patients weaning from mechanical ventilation, HFNC shows advantages over NIV 3:

  • Higher PaO2 (MD=2.95, p<0.00001)
  • Lower PaCO2 (MD=-3.04, p<0.00001)
  • Lower re-intubation rates (OR=0.45, p<0.00001)
  • Shorter ICU stays (MD=-6.15 days, p<0.00001)
  • No difference in mortality or infection rates

Acute Hypoxemic Respiratory Failure

CPAP is superior to HFNC for acute hypoxemic respiratory failure 4:

  • CPAP reduced risk of meeting intubation criteria by 67% (HR=0.327, p=0.006)
  • Better oxygenation with CPAP
  • No mortality difference, but CPAP prevents deterioration more effectively

Clinical Algorithm

For aerosol medication delivery with airway clearance:

  • Use Metaneb/BiWaze Clear systems (4-5x better lung deposition than Volara)

For oxygen therapy/respiratory support:

  • Post-extubation weaning: HFNC is appropriate and effective
  • Acute hypoxemic respiratory failure: Use CPAP first-line, not HFNC
  • COPD or hypercapnia risk: Avoid HFNC; use Venturi masks (24-28%) or low-flow nasal cannula (1-2 L/min) 2

Critical Caveats

  • Volara's primary weakness is as a nebulizer delivery system, not necessarily as an HFNC device for oxygen therapy
  • The 1997 nebulizer guidelines 5 establish that proper nebulization requires 6-8 L/min flow and appropriate particle sizing—Volara's design fails to optimize drug delivery
  • Never use HFNC in patients at risk of CO2 retention without close monitoring 2
  • Equipment choice matters significantly: circuit design, nebulizer type, and handset configuration directly impact clinical effectiveness 1

References

Related Questions

What is the stepwise progression of airway management using a nasal cannula, a non‑rebreather mask, a bag‑valve‑mask, continuous positive airway pressure (CPAP), a laryngeal mask airway, and endotracheal intubation?
Does continuous positive airway pressure (CPAP) need to be adjusted for high altitude?
A 10‑day postpartum woman presents with dysuria and a urine culture growing mixed microbiota >100,000 CFU/mL; how should this be managed?
In a 10‑month‑old infant with a slightly indented coronal suture, normal fontanelles, and appropriate head growth, what is the appropriate next step in management?
What is the appropriate 10‑day antibiotic regimen for a patient undergoing ENT follow‑up after image‑guided fine‑needle aspiration/biopsy, assuming no documented β‑lactam allergy?
When is N‑acetylcysteine (Mucomyst) preferred over 3 % sodium chloride (hypertonic saline) for nebulized therapy, and what are the recommended dosing and precautions?
How is the stool osmolar gap calculated and what do high versus low values indicate about osmotic versus secretory diarrhea?
Is it safe to use Inotyol (10% urea) cream in a 9‑month‑old infant with mild atopic dermatitis, and what alternative moisturizers or precautions are recommended?
What is airway closure, including its pathophysiology, clinical signs, and management?
For a patient with invasive ductal carcinoma (IDC), how long should tamoxifen therapy be continued?
What renal manifestations can cytomegalovirus (CMV) cause and what is the recommended treatment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.